Search Results

Emtora Biosciences, Inc., a privately-held, San Antonio-based biotechnology company developing a novel reformulated version of a previously-approved drug today announced the acceptance of an abstract for oral presentation at the upcoming Digestive Disease Week (“DDW”) Annual Meeting.

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) is pleased to announce that’s its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (“FAP”) are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024.

Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.

Emtora Biosciences announced it has been awarded a $16.9M non-dilutive grant from the Cancer Prevention & Research Institute of Texas to advance the clinical and product development of its lead program, eRapaTM, an encapsulated form of rapamycin, for the treatment of Familial Adenomatous Polyposis.